Strs Ohio Decreases Holdings in Pfizer Inc. $PFE

Key Points

• Strs Ohio trimmed its stake in Pfizer by 4.9% in Q4, selling 111,847 shares and now holds 2,173,382 shares valued at about $54.12 million, while institutional investors own roughly 68.36% of the stock.
• Pfizer beat Q4 expectations with EPS of $0.66 versus $0.57 and revenue of $17.56 billion; the stock trades in the mid‑$20s with a market cap near $149.8 billion and a PE of 19.37.
• Pfizer announced a $0.43 quarterly dividend (ex‑dividend May 8) implying a 6.5% yield but a 126.47% payout ratio, and it has recent regulatory/pipeline wins (FDA approval for a Pfizer–Arvinas breast cancer therapy and Vyndamax patent settlements to 2031) amid mixed analyst ratings and a consensus "Hold."

Strs Ohio trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,173,382 shares of the biopharmaceutical company's stock after selling 111,847 shares during the period. Strs Ohio's holdings in Pfizer were worth $54,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PFE. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer during the 3rd quarter valued at approximately $3,019,000. Money Concepts Capital Corp boosted its stake in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock valued at $6,325,000 after buying an additional 57,188 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer during the 3rd quarter valued at approximately $16,613,000. Penn Davis Mcfarland Inc. boosted its stake in shares of Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock valued at $4,266,000 after buying an additional 57,777 shares during the last quarter. Finally, Callahan Advisors LLC boosted its stake in shares of Pfizer by 6.5% during the 3rd quarter. Callahan Advisors LLC now owns 713,797 shares of the biopharmaceutical company's stock valued at $18,188,000 after buying an additional 43,454 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $26.35 on Friday. The business's fifty day moving average price is $27.17 and its 200 day moving average price is $26.09. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75. The stock has a market capitalization of $149.80 billion, a PE ratio of 19.37 and a beta of 0.35. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. During the same period last year, the business posted $0.63 earnings per share. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer's dividend payout ratio (DPR) is 126.47%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Royal Bank Of Canada reiterated an "underperform" rating and set a $25.00 target price on shares of Pfizer in a research note on Monday, April 20th. BMO Capital Markets reiterated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They set an "outperform" rating and a $33.00 target price for the company. Barclays initiated coverage on Pfizer in a research note on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price for the company. Finally, HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.74.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.